Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 11 Nov 2021
FDA touts success and challenges in biosimilar development
10 November 2021 - A top official from the US FDA offered a mixed assessment of the agency’s biosimilars program, noting ...
Posted by Michael Wonder on 11 Nov 2021
Health tech questions await next FDA chief
10 November 2021 - Twenty months into the pandemic, the FDA remains consumed with vital decisions on coronavirus vaccines and treatments. ...
Posted by Michael Wonder on 11 Nov 2021
Bolstering our ability to value health technology: a few less considered issues
9 November 2021 - Proposals for a national entity to produce and assess evidence about the relative value of medical technology ...
Posted by Michael Wonder on 11 Nov 2021
Inclusion in health technology assessments: the first step toward equity
10 November 2021 - Many researchers working on health technology assessments are keen to address disparities in health care. ...
Posted by Michael Wonder on 11 Nov 2021
European Council green lights new rules on health technology assessment, improving access to medicines and simplifying procedures
9 November 2021 - The Council today gave its final go-ahead for the adoption of a regulation on health technology assessment. ...
Posted by Michael Wonder on 11 Nov 2021
Average family premiums for employer-based health insurance have jumped 47% in the last decade, outpacing wage growth and inflation
11 November 2021 - You’re not imagining the growing pinch to your budget from the cost of your workplace health ...
Posted by Michael Wonder on 11 Nov 2021
Patient access to affordable cancer treatment increases with the launch of new biosimilar in Canada
9 November 2021 - Apobiologix today launched its first oncology therapeutic treatment Bambevi (bevacizumab), which is used in combination with ...
Posted by Michael Wonder on 11 Nov 2021
US FDA accepts supplemental new drug application and grants priority review for Jardiance for adults with heart failure independent of left ventricular ejection fraction
11 November 2021 - If approved, Jardiance would be the first clinically proven treatment for adults across the full spectrum ...
Posted by Michael Wonder on 11 Nov 2021
Valneva receives EU deal for COVID jab, and seeks apology from UK
11 November 2021 - French vaccine manufacturer, Valneva, has announced that it has won EU approval to supply up to 60 ...
Posted by Michael Wonder on 11 Nov 2021
COVID-19: EMA recommends authorisation of two monoclonal antibody medicines
11 November 2021 - EMA’s CHMP has recommended authorising Ronapreve (casirivimab/imdevimab) and Regkirona (regdanvimab) for COVID-19. ...
Posted by Michael Wonder on 11 Nov 2021
Moderna booster progress ‘well advanced’ as regulator considers child vaccines
11 November 2021 - Moderna’s coronavirus vaccine could be approved for use as a booster within weeks and the medical ...
Posted by Michael Wonder on 11 Nov 2021
HSE approves reimbursement of Ajovy (fremanezumab) in migraine
11 November 2021 - Teva Pharmaceuticals Ireland has announced the approval of Ajovy (fremanezumab) 225 mg pre-filled syringe for prescription ...
Posted by Michael Wonder on 11 Nov 2021
Tremfya (guselkumab) approved for reimbursement in Ireland for active psoriatic arthritis
11 November 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson have announced that Tremfya (guselkumab), a first-in-class treatment ...
Posted by Michael Wonder on 11 Nov 2021
COVID-19 vaccine weekly safety report (11 November 2021)
11 November 2021 - To 7 November 2021, the TGA has received 288 reports which have been assessed as likely to ...
Posted by Michael Wonder on 10 Nov 2021
NICE terminates appraisal of new, first in class radioenhancer hafnium oxide nanoparticle
10 November 2021 - NBTXR3 is used to treat patients with sarcoma. ...